9 research outputs found
Factors associated with late stage at diagnosis among Puerto Rico’s government health plan colorectal cancer patients: a cross-sectional study
Factors associated with late stage at diagnosis among Puerto Rico’s government health plan colorectal cancer patients: a cross-sectional study
Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study
<div><p>Objective</p><p>This study aims to examine factors associated with the use of adjuvant chemotherapy and the use of oxaliplatin after curative resection in stage III colon cancer patients and assesses the effect of their use in three-year survival.</p><p>Methods</p><p>This retrospective cohort study was conducted using Puerto Rico Central Cancer Registry-Health Insurance Linkage Database. The study cohort consisted of stage III colon cancer patients with a curative surgery in the period 2008–2012. Multivariate logistic regression was used to estimate adjusted odds ratios. Kaplan-Meier methods and Cox proportional hazards models were used to assess the association between adjuvant chemotherapy and oxaliplatin use and overall survival and risk of death, respectively.</p><p>Results</p><p>Overall, 75% of the study population received adjuvant chemotherapy during the study period. Factors statistically associated with receiving adjuvant chemotherapy within four months after resection included being married (adjusted odds ratio [AOR] 1.64; 95% CI 1.18–2.28; p = 0.003), and being enrolled in Medicare (AOR 1.68; 95% CI: 1.03–2.75; p = 0.039) or Medicaid and Medicare dual eligible (AOR 1.66; 95% CI: 1.06–2.60; p = 0.028). However, patients aged ≥70 years were less likely to receive adjuvant chemotherapy (AOR 0.22; 95%CI 0.14–0.36; p<0.001).</p><p>Discussion</p><p>We observed a significant reduction in mortality in adjuvant chemotherapy treated patients. Similarly, patients <70 years treated with oxaliplatin had significantly lower risk of death than those who did not, although for patients ≥70 years no statistical significance was achieved. Future studies should assess effective interventions to reduce barriers to access guideline-based recommended colon cancer treatment.</p></div
Three-year overall survival according to the Receipt of oxaliplatin among patients receiving ACT by age group (<70 years and ≥70 years).
<p>Three-year overall survival according to the Receipt of oxaliplatin among patients receiving ACT by age group (<70 years and ≥70 years).</p
Characteristics of stage III colon cancer patients who used ACT by oxaliplatin Receipt status.
<p>Characteristics of stage III colon cancer patients who used ACT by oxaliplatin Receipt status.</p
Three-year overall survival according to the Receipt of ACT stratified by age group (<70 years and ≥70 years) ACT = adjuvant chemotherapy.
<p>Three-year overall survival according to the Receipt of ACT stratified by age group (<70 years and ≥70 years) ACT = adjuvant chemotherapy.</p
Characteristics of stage III colon cancer patients by adjuvant chemotherapy (ACT) status.
<p>Characteristics of stage III colon cancer patients by adjuvant chemotherapy (ACT) status.</p